Kmyta O. Clinical course of traumatic brain injury with regard to -675 4G/5G polymorphism of plasminogen activator inhibitor-1 gene

The thesis concerns the influence of -675 4G/5G polymorphism of plasminogen activator inhibitor-1 gene on the clinical course of traumatic brain injury and development of secondary cerebral ischemic disorders. The influence of -675 4G/5G polymorphism of plasminogen activator inhibitor-1 gene was investigated in 200 patients with traumatic brain injury and 95 apparently healthy individuals. It was shown in the thesis that 4G/4G and 4G/5G genotypes of -675 4G/5G polymorphism of plasminogen activator inhibitor-1 gene are associated with higher incidence of secondary cerebral ischemic disorders in patients with severe traumatic brain injury, high plasma concentration of plasminogen activator inhibitor-1 and more severe clinical course of traumatic brain injury as compared to the carriers of 5G/5G genotype. New approaches were substantiated for monitoring of hemostatic profile changes in patients with traumatic brain injury, especially in those having severe traumatic brain injuries and overweight or obesity depending on the genotype of -675 4G/5G polymorphism of plasminogen activator inhibitor-1 gene in order to provide early prevention measures for ischemic complications: 4G/4G and 4G/5G genotype carriers with obesity have higher plasma concentration of plasminogen activator inhibitor-1, as compared to the patients with mild traumatic brain injury, normal weight and 5G/5G genotype, which can lead to fibrinolytic system disorders and secondary cerebral ischemic disorders.